Miltefosine is a topic covered in the Johns Hopkins Antibiotic (ABX) Guide.

To view the entire topic, please or purchase a subscription.

Johns Hopkins Guides provide diagnosis, management, and treatment guidance for infectious diseases, diabetes, and psychiatric conditions. Explore these free sample topics:

Johns Hopkins Guides

~~ The first section of this topic is shown below ~~

INDICATIONS

FDA

  • Miltefosine is available under an expanded access IND form the CDC (770-488-7100) in the U.S. for the treatment of free-living ameba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
  • Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.

NON-FDA APPROVED USES

  • Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans

~~ To view the remaining sections of this topic, please
or purchase a subscription ~~

Last updated: April 5, 2016